Thiard News@F4F

@newsen.bsky.social

4 days ago

Hoth Therapeutics Unveils Promising Findings in HT-VA Study, GDNF Revolutionizes Liver Fat Metabolism Hoth Therapeutics announces groundbreaking results from the HT-VA study, showcasing how GDNF influences liver fat metabolism, outperforming traditional therapies.

Hoth Therapeutics Unveils Promising Findings in HT-VA Study, GDNF Revolutionizes Liver Fat Metabolism #USA #New_York #Hoth_Therapeutics #GDNF #HT-VA_Study

Thiard News@F4F

@newsen.bsky.social

4 days ago

Hoth Therapeutics' Groundbreaking HT-VA Study Shows GDNF Outperforms Semaglutide for Liver Fat Reprogramming Hoth Therapeutics showcases impressive results from its HT-VA study, revealing GDNF's ability to outperform Semaglutide in liver fat metabolism, presenting a new frontier in metabolic therapies.

Hoth Therapeutics' Groundbreaking HT-VA Study Shows GDNF Outperforms Semaglutide for Liver Fat Reprogramming #United_States #New_York #Semaglutide #Hoth_Therapeutics #GDNF

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Hoth Therapeutics Closes $2 Million Offering to Fuel Innovative Therapies Hoth Therapeutics has successfully closed a registered direct offering worth $2 million, aimed at advancing its clinical-stage innovations in biopharmaceuticals.

Hoth Therapeutics Closes $2 Million Offering to Fuel Innovative Therapies #USA #New_York #Clinical_Trials #biotechnology #Hoth_Therapeutics

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Hoth Therapeutics Secures $2 Million Funding through Registered Direct Offering Hoth Therapeutics has announced a successful $2 million registered direct offering, aiming to enhance its clinical-stage biopharmaceutical initiatives and improve patient care.

Hoth Therapeutics Secures $2 Million Funding through Registered Direct Offering #USA #New_York #Biopharmaceutical #Hoth_Therapeutics #NASDAQ_HOTH

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Hoth Therapeutics' HT-001 Scores Approval in Hungary After Successful Clinical Trial Phase Hoth Therapeutics' HT-001 demonstrates promising clinical results, achieving key endpoints and gaining regulatory approval for trial expansion in Hungary, paving the way for broader patient enrollment.

Hoth Therapeutics' HT-001 Scores Approval in Hungary After Successful Clinical Trial Phase #None #Clinical_Trials #Hoth_Therapeutics #HT-001

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Hoth Therapeutics Secures Chinese Patent for Revolutionary Cancer Cell Targeting Technology Hoth Therapeutics has received a crucial patent in China for its innovative therapeutic platform targeting cancer cells, reinforcing its global presence.

Hoth Therapeutics Secures Chinese Patent for Revolutionary Cancer Cell Targeting Technology #United_States #New_York #Hoth_Therapeutics #Patent_Technology #Cancer_Cells

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Hoth Therapeutics Unveils OpenClaw™ AI Platform to Propel Drug Discovery Efforts Hoth Therapeutics, Inc. launches OpenClaw™, an advanced AI platform aimed at speeding up drug discovery and improving data-driven decisions across its therapeutic pipeline.

Hoth Therapeutics Unveils OpenClaw™ AI Platform to Propel Drug Discovery Efforts #USA #New_York #Hoth_Therapeutics #AI_in_Pharma #OpenClaw

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities Hoth Therapeutics has announced remarkable results from the HT-001 study, showcasing improved drug exposure and safety for cancer patients suffering skin toxicities.

Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities #United_States #New_York #Hoth_Therapeutics #HT-001 #EGFR_Therapy

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hoth Therapeutics Delivers Promising Preclinical Results for HT-VA on Lipid Metabolism and Cholesterol Restoration Hoth Therapeutics presents encouraging preclinical outcomes for HT-VA, highlighting its potential in restoring cholesterol levels and improving lipid metabolism.

Hoth Therapeutics Delivers Promising Preclinical Results for HT-VA on Lipid Metabolism and Cholesterol Restoration #USA #New_York #Hoth_Therapeutics #GDNF #HT-VA

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hoth Therapeutics Utilizes OpenAI API to Enhance Orphan Drug Program Development Hoth Therapeutics has integrated OpenAI's technology into its development process for HT-KIT, targeting rare KIT-driven cancers. This move advances the IND preparation and supports clinical progression.

Hoth Therapeutics Utilizes OpenAI API to Enhance Orphan Drug Program Development #United_States #New_York #Hoth_Therapeutics #HT-KIT #OpenAI_API

Thiard News@F4F

@newsen.bsky.social

1 month ago

Hoth Therapeutics Expands Clinical Trial Network Amid Rising Patient Demand for HT-001 Therapy Hoth Therapeutics is ramping up its CLEER-001 Phase 2a clinical trial by adding new sites due to increased patient interest, signaling potential breakthroughs in cancer treatment.

Hoth Therapeutics Expands Clinical Trial Network Amid Rising Patient Demand for HT-001 Therapy #USA #Miami #Hoth_Therapeutics #HT-001 #CLEER-001

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hoth Therapeutics Achieves Notice of Allowance For Innovative Allergy Treatment Patent Hoth Therapeutics has received a Notice of Allowance for a groundbreaking patent on a new therapy aimed at treating allergic diseases. This advanced method offers a fresh approach to immunomodulation.

Hoth Therapeutics Achieves Notice of Allowance For Innovative Allergy Treatment Patent #United_States #New_York #Hoth_Therapeutics #Allergy_Treatment #Immunology

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hoth Therapeutics' HT-VA GDNF Outperforms Semaglutide in Obesity Treatment Breakthrough Hoth Therapeutics reveals that its HT-VA GDNF shows superior weight loss, glucose control, and liver health results compared to Semaglutide, hinting at a new era in obesity treatment.

Hoth Therapeutics' HT-VA GDNF Outperforms Semaglutide in Obesity Treatment Breakthrough #USA #New_York #Semaglutide #Hoth_Therapeutics #HT-VA_GDNF

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hoth Therapeutics Clarifies Rumors: No Cryptocurrency Assets Held by Company Hoth Therapeutics has addressed recent market rumors regarding its exposure to cryptocurrencies, confirming that it holds no crypto assets.

Hoth Therapeutics Clarifies Rumors: No Cryptocurrency Assets Held by Company #USA #New_York #Clinical_Trials #biotechnology #Hoth_Therapeutics

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hoth Therapeutics Reports Groundbreaking Results in Cancer Treatment with HT-001 Therapy Hoth Therapeutics has achieved remarkable results in treating cancer. Their HT-001 therapy shows a 100% clinical response rate and substantial reductions in disease severity and patient-reported symptoms.

Hoth Therapeutics Reports Groundbreaking Results in Cancer Treatment with HT-001 Therapy #USA #New_York #Cancer_Treatment #Hoth_Therapeutics #HT-001

Thiard News@F4F

@newsen.bsky.social

2 months ago

Hoth Therapeutics Achieves Significant Patent Approval for Innovative HT-KIT Cancer Treatment Hoth Therapeutics has secured an important international patent for its HT-KIT cancer program, enhancing its oncology intellectual property in China, the world's key market.

Hoth Therapeutics Achieves Significant Patent Approval for Innovative HT-KIT Cancer Treatment #United_States #New_York #Cancer_Treatment #Hoth_Therapeutics #HT-KIT

Thiard News@F4F

@newsen.bsky.social

3 months ago

Hoth Therapeutics Achieves Milestone for HT-001 Oncology Trial in Europe Hoth Therapeutics has successfully reached a significant EU regulation milestone for its HT-001 trial, aimed at advancing oncology treatment across multiple countries.

Hoth Therapeutics Achieves Milestone for HT-001 Oncology Trial in Europe #United_States #New_York #oncology #Hoth_Therapeutics #HT-001

Thiard News@F4F

@newsen.bsky.social

3 months ago

Hoth Therapeutics Takes Steps Towards Breakthroughs in Oncology Dermatology with New Patents Hoth Therapeutics has secured two provisional patents aimed at addressing skin toxicity issues in oncology patients, significantly expanding their treatment options.

Hoth Therapeutics Takes Steps Towards Breakthroughs in Oncology Dermatology with New Patents #USA #New_York #Hoth_Therapeutics #HT-001 #oncology_patents

Thiard News@F4F

@newsen.bsky.social

4 months ago

Hoth Therapeutics Provides Exciting Progress on Its Clinical Pipeline Development Hoth Therapeutics has released an update on its drug development efforts, showcasing advancements in several clinical programs, including HT-001 and HT-KIT.

Hoth Therapeutics Provides Exciting Progress on Its Clinical Pipeline Development #USA #New_York #Hoth_Therapeutics #HT-001 #HT-KIT

Thiard News@F4F

@newsen.bsky.social

4 months ago

Hoth Therapeutics Set to Present Innovative Biopharmaceutical Solutions at 2025 Noble Capital Markets Conference Hoth Therapeutics will showcase its groundbreaking biopharmaceutical developments at the 21st Annual Noble Capital Markets Conference in Boca Raton, FL, December 2-3, 2025.

Hoth Therapeutics Set to Present Innovative Biopharmaceutical Solutions at 2025 Noble Capital Markets Conference #United_States #Boca_Raton #Biopharmaceutical #Hoth_Therapeutics #Noble_Capital

Thiard News@F4F

@newsen.bsky.social

4 months ago

Hoth Therapeutics Joins NVIDIA Connect Program to Enhance AI Capabilities Hoth Therapeutics has officially joined the NVIDIA Connect Program, gaining advanced AI tools and support to accelerate its drug development efforts.

Hoth Therapeutics Joins NVIDIA Connect Program to Enhance AI Capabilities #United_States #New_York #Hoth_Therapeutics #AI_Capabilities #NVIDIA_Connect

Thiard News@F4F

@newsen.bsky.social

5 months ago

Hoth Therapeutics Unveils Innovative GDNF Weight Loss Therapy Study with VA Partnership Hoth Therapeutics has launched a groundbreaking study backed by the VA to explore GDNF therapy for obesity and fatty liver disease, paving the way for new treatments.

Hoth Therapeutics Unveils Innovative GDNF Weight Loss Therapy Study with VA Partnership #Hoth_Therapeutics #GDNF #Obesity_Therapy

Thiard News@F4F

@newsen.bsky.social

5 months ago

Hoth Therapeutics Advances HT-KIT with FDA Orphan Drug Designation and Preclinical Promises Discover how Hoth Therapeutics' HT-KIT received FDA Orphan Drug Designation, showcasing promising preclinical data in fighting rare cancers.

Hoth Therapeutics Advances HT-KIT with FDA Orphan Drug Designation and Preclinical Promises #USA #New_York #FDA #Hoth_Therapeutics #HT-KIT

Thiard News@F4F

@newsen.bsky.social

6 months ago

Hoth Therapeutics Leverages NVIDIA AI to Innovate Drug Development Initiatives Hoth Therapeutics is advancing its AI initiatives by partnering with NVIDIA to enhance their drug development processes, unlocking new capabilities.

Hoth Therapeutics Leverages NVIDIA AI to Innovate Drug Development Initiatives #United_States #New_York #Drug_Development #Hoth_Therapeutics #NVIDIA_AI

Thiard News@F4F

@newsen.bsky.social

6 months ago

Hoth Therapeutics CEO Robb Knie to Showcase Innovations at BIO-Europe 2025 in Vienna CEO Robb Knie of Hoth Therapeutics will present key clinical advancements at BIO-Europe 2025, focusing on innovative cancer therapies in Vienna.

Hoth Therapeutics CEO Robb Knie to Showcase Innovations at BIO-Europe 2025 in Vienna #Vienna #Austria #Hoth_Therapeutics #Robb_Knie #BIO-Europe

Thiard News@F4F

@newsen.bsky.social

6 months ago

Hoth Therapeutics Expands Patent Portfolio for HT-001 to Combat Severe Skin Toxicities in Oncology Treatments Hoth Therapeutics has announced the expansion of its patent filings for HT-001, targeting skin toxicities related to cancer therapies, enhancing patient care and drug efficacy.

Hoth Therapeutics Expands Patent Portfolio for HT-001 to Combat Severe Skin Toxicities in Oncology Treatments #USA #New_York #Hoth_Therapeutics #HT-001 #Menin_Inhibitors

Thiard News@F4F

@newsen.bsky.social

7 months ago

Hoth Therapeutics Strengthens Position with Major Developments and Shareholder Update Hoth Therapeutics, Inc. has announced a significant shareholder update highlighting advancements in clinical programs and innovative treasury strategies.

Hoth Therapeutics Strengthens Position with Major Developments and Shareholder Update #USA #New_York #Hoth_Therapeutics #HT-001 #VA_Obesity_Program

Thiard News@F4F

@newsen.bsky.social

7 months ago

Hoth Therapeutics Partners with Lantern Pharma for Revolutionary Predictive AI in Drug Development Hoth Therapeutics is utilizing Lantern Pharma's PredictBBB.ai platform, enhancing drug development efficiency with AI boasting 94% accuracy in drug permeability predictions.

Hoth Therapeutics Partners with Lantern Pharma for Revolutionary Predictive AI in Drug Development #United_States #New_York #Hoth_Therapeutics #Lantern_Pharma #PredictBBB.ai

Thiard News@F4F

@newsen.bsky.social

7 months ago

Hoth Therapeutics' HT-KIT Demonstrates Promising Anti-Tumor Efficacy and Bioanalytical Validation Hoth Therapeutics announces significant milestones for its cancer therapeutic HT-KIT, showcasing anti-tumor activity and meeting GLP standards.

Hoth Therapeutics' HT-KIT Demonstrates Promising Anti-Tumor Efficacy and Bioanalytical Validation #United_States #New_York #oncology #Hoth_Therapeutics #HT-KIT

Thiard News@F4F

@newsen.bsky.social

8 months ago

Hoth Therapeutics Expands Clinical Trial Phase II in Europe to Treat Cancer-Related Skin Toxicities Hoth Therapeutics has partnered with ICON Clinical Research to expand its Phase II clinical trial in Europe for HT-001, targeting skin toxicities in cancer patients.

Hoth Therapeutics Expands Clinical Trial Phase II in Europe to Treat Cancer-Related Skin Toxicities #None #Hoth_Therapeutics #HT-001 #ICON_Clinical